Table 1.

Comparison of UraBT indices from subjects with normal DPD activity and partial and profound DPD deficiency

Normal activity (n = 19)Partial DPD deficiency (n = 11)Profound DPD deficiency (n = 1)
DOB50 (DOB)*183.2 ± 31.283.7 ± 25.30.9
Cmax (DOB)*193.8 ± 28.1121.8 ± 36.73.6
Tmax (min)*50.5 ± 10.8125.4 ± 43.2120.0
AUCτ (‰ min)*21,597.1 ± 2,634.215,572.9 ± 4,327.4348.7
PDR*55.7 ± 4.939.8 ± 9.9<1.0
DPD activity (nmol/min/mg)*0.27 ± 0.060.11 ± 0.05Undetectable
  • NOTE: Data were obtained from 19 subjects with normal DPD activity, 11 subjects with partial DPD deficiency, and 1 subject with profound DPD deficiency following oral administration of [2-13C]uracil (6 mg/kg dose). Data are mean ± SD.

  • * DOB50, 13CO2 concentration in breath (DOB) 50 minutes after [2-13C]uracil administration; Cmax, maximum concentration of 13CO2 in breath; Tmax, time to Cmax; AUCτ, area under the 13CO2 breath curve; PDR, percent dose of [2-13C]uracil recovered in the breath as 13CO2; DPD activity, fresh PBMC DPD enzyme activity.

  • P < 0.05 for both pairwise comparisons (normal DPD activity versus partial DPD deficiency and normal DPD activity versus profound DPD deficiency).

  • P < 0.05 (normal DPD activity versus partial DPD deficiency).